Press Releases :: Beyond Air Inc. (XAIR)

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in March 2021

Mar 01, 2021 8:00am EST

Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease

Feb 16, 2021 8:00am EST

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update

Feb 09, 2021 4:05pm EST

Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Jan 15, 2021 4:10pm EST

Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease

Dec 07, 2020 8:00am EST

Beyond Air® to Participate in the 32nd Annual Piper Sandler Healthcare Conference from December 1-3, 2020

Nov 19, 2020 8:00am EST

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update

Nov 11, 2020 4:10pm EST

Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn

Nov 11, 2020 7:30am EST

Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Oct 23, 2020 8:00am EDT

Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19

Oct 21, 2020 7:00am EDT

1
2
3
4
5
6
7
8
9
10
...13

Important Safety Information

^†Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.